文献速递妇科

晚期/复发性子宫内膜癌治疗:超越卡铂与紫杉醇的探索

Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer.
PubMed 文献 · Gynecol Oncol · 2022-10-22

子宫内膜癌发病率与死亡率在各族裔中均上升,卡铂联合紫杉醇是晚期/复发性疾病既定一线治疗,后续传统细胞毒化疗困难。分子分型促进免疫治疗与靶向治疗发展,包括帕博利珠单抗、多塔利单抗和仑伐替尼;铂类再挑战的「铂敏感」定义主观且基于专家意见,小样本回顾性研究受限,本文综述铂双药再挑战数据及最新进展。

要点

  • 卡铂联合紫杉醇是晚期/复发性子宫内膜癌的既定一线治疗。
  • 分子分型推动帕博利珠单抗、多塔利单抗及仑伐替尼等精准治疗发展。
  • 铂类再挑战的「铂敏感」定义主观,基于专家意见或实践者经验。

核心结论

  • 本文综述铂双药化疗再挑战的现有数据,并强调子宫内膜癌治疗的最新关键进展及未来方向。

研究设计与样本

  • 综述,检索范围未在原文中报告。

主要发现

  • 子宫内膜癌发病率与死亡率在各族裔中均上升。
  • 卡铂联合紫杉醇是晚期/复发性子宫内膜癌的既定一线治疗。
  • 分子特征分析促进帕博利珠单抗、多塔利单抗和仑伐替尼等精准免疫治疗与靶向治疗的发展。
  • 铂类再挑战的「铂敏感」在子宫内膜癌中主观,主要基于专家意见和/或实践者经验。
  • 小型回顾性研究因患者特征多变和样本量小受限,且患者人口学变化、对驱动因素理解加深及免疫检查点抑制剂和仑伐替尼联合帕博利珠单抗二线获批使这些回顾性研究的适用性困难。

局限性

  • 铂类再挑战的「铂敏感」在子宫内膜癌中主观,主要基于专家意见和/或实践者经验。
  • 小型回顾性研究因患者特征多变和样本量小受限。
  • 患者人口学变化、对子宫内膜癌驱动因素理解加深及近期免疫检查点抑制剂和仑伐替尼联合帕博利珠单抗二线获批,使这些回顾性研究对当代临床实践的适用性困难。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Endometrial cancer incidence and mortality are rising among all ethnic groups. Carboplatin plus paclitaxel is the established frontline treatment for advanced/recurrent disease; however, subsequent treatment with traditional cytotoxic chemotherapy is challenging. The molecular characterization of endometrial cancer has provided important insights into the biological drivers of carcinogenesis, which has allowed for the development of newer precision immunotherapies and targeted therapies, including pembrolizumab, dostarlimab, and lenvatinib. Until recently, platinum rechallenge was often considered at the time of recurrence, given the lack of other available therapeutic options; however, "platinum sensitivity" in endometrial cancer is subjective and largely based on expert opinion and/or practitioner experience. Small retrospective studies have tried to provide guidance on the utility of platinum rechallenge, but they are limited by variable patient characteristics and small sample sizes. The applicability of these retrospective studies to contemporary clinical practice is difficult in the setting of changing patient demographics, a better understanding of endometrial cancer drivers, and the recent approvals of immune checkpoint inhibitors and the combination of lenvatinib plus pembrolizumab in the second-line setting. The primary focus of this review is to distill the available data regarding platinum-doublet chemotherapy rechallenge and highlight recent pivotal developments in endometrial cancer treatment, as well as future directions.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Rubinstein M, Shen S, Monk BJ, et al. Looking beyond carboplatin and paclitaxel for the treatment of advanced/recurrent endometrial cancer. Gynecol Oncol. 2022. PMID: 36280455. doi:10.1016/j.ygyno.2022.10.012

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。